PeptidesInfo

Comparison

BPC-157 vs TB-500

The two most popular "healing peptides" compared on what has actually been studied, in whom, and what the FDA has said about each.

Updated

Bottom line

Neither peptide has controlled human evidence for healing. BPC-157 has a larger animal literature, concentrated in a small number of laboratories; TB-500 borrows credibility from the full-length thymosin beta-4, which has early human trials the fragment does not. Both are unapproved, and neither can lawfully be compounded: both were placed in the FDA's category 2 in September 2023 over immunogenicity and impurity concerns, and both now sit on the withdrawn-nomination list, which removes the listing without adding them to the 503A bulks list.

Dimension
BPC-157
Preclinical evidenceNot FDA-approved
TB-500
Preclinical evidenceNot FDA-approved
What it isSynthetic 15-amino-acid fragment derived from a gastric proteinMarketed as a fragment of thymosin beta-4 (a 43-amino-acid natural peptide)
Human evidenceOne small published safety/pharmacokinetic dataset; case reports; no controlled efficacy trialNone for TB-500 itself; phase 1/2 trials exist for full-length thymosin beta-4 in wounds and eye conditions
Animal evidenceExtensive: tendon, ligament, muscle, gut, vascular models, mostly ratsModerate: dermal wound, cardiac and corneal models for thymosin beta-4
Evidence level (recovery)PreclinicalPreclinical
US regulatory statusNot FDA-approved; category 2 nomination withdrawn (still not compoundable)Not FDA-approved; thymosin beta-4 investigational in registered trials
Safety dataAnimal toxicology plus one small human dataset; long-term unknownTolerability reported in thymosin beta-4 trials; none for the fragment
Anti-doping statusProhibited by WADA (S0, non-approved substances)Prohibited by WADA (S2.3, growth factors)

Why people compare them

Both are sold for tendon, ligament and muscle recovery, often together as a "healing stack". Both have plausible mechanisms in animal models — BPC-157 via angiogenic and nitric-oxide pathways, thymosin beta-4 via actin sequestration and cell migration. And both are conspicuously absent from clinical practice, which is the first clue about the state of the evidence.

The important asymmetry

BPC-157's literature is large but narrow: hundreds of animal papers, a majority from a single research group in Zagreb, and until recently no human trials at all. TB-500's literature is borrowed: the papers cited for it are almost always about full-length thymosin beta-4, a different molecule that has been through early human trials for dermal wounds and eye disease. Whether the fragment sold as TB-500 behaves like the parent peptide in humans has not been tested.

What would settle it

A randomised, placebo-controlled human trial in a defined injury with a functional endpoint. As of our last update we can find no such trial with posted results for either compound. Until then, "which is better?" has no evidence-based answer — and "does either work in people?" is still open.

Go deeper

Research analysis6 min read

BPC-157: Human Evidence, Animal Research, and Open Questions

BPC-157 has hundreds of positive animal studies and almost no controlled human data. We separate what the rat research shows, what the few human reports show, what the FDA has said, and what would have to happen for the evidence grade to change.

Research analysis4 min read

TB-500 and Thymosin Beta-4: What the Research Actually Studies

TB-500 is sold on the back of thymosin beta-4 research — a different molecule with real but early human trials in wounds and eye disease. We untangle which studies are about what, and what that means for the fragment people actually buy.